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People with metastatic breast cancer face many challenges and disparities in obtaining optimal cancer
care. These challenges are accentuated in underserved patient populations across Europe, who are less
likely to receive quality healthcare for reasons including socioeconomic inequalities, educational or
cultural status, or geographic location. While there are many local and national initiatives targeted to
address these challenges, there remains a need to reduce disparities and improve access to healthcare to
improve outcomes, with a focus on multidisciplinary stakeholder engagement.
In October 2019, a range of experts in metastatic breast cancer, including healthcare professionals,
patient representatives, policymakers and politicians, met to discuss and prioritize the critical needs of
underserved patient populations with metastatic breast cancer in Europe. Six key challenges faced by
these communities were identified: the need for amplification of the metastatic breast cancer patient
voice, better and wider implementation of high-quality guidelines for metastatic breast cancer, more
collaboration between stakeholders, tailored support for patients from different cultural and ethnic
backgrounds, improved data sharing, and work-related issues. The Expert Panel then conceived and
discussed potential actionable goals to address each key challenge. Their conclusions present a set ofd Clinical Center/Champalimaud Foundation, Av. Brasília, Lisbon, 1400-038, Portugal.
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E. Vrdoljak, J. Gligorov, L. Wierinck et al. The Breast 55 (2021) 79e90interrelated approaches to address the different challenges and could serve as the basis for concerted
improvement of the lives of patients with metastatic breast cancer in Europe.
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Breast cancer (BC) is the most commonly diagnosed cancer and
the leading cause of cancer-related death in women across Europe
[1]. Although early BC is treatable and potentially curable, up to 10%
of patients are diagnosed at an advanced stage in developed
countries, and 20e30% of patients experience progression to met-
astatic BC (mBC), even if diagnosed early and appropriately
managed [2,3]. Despite advancements in our understanding of the
disease, mBC survival rates have remained stable [2,4e7], although
available data pre-date the advent of treatments such as cyclin-
dependent kinase 4/6 and phosphoinositide 3-kinase inhibitors
[8], newer human epidermal growth factor receptor 2 (HER2) tar-
geted agents [9], poly-ADP ribose polymerase inhibitors [10] and a
PD-L1 inhibitor [11], which will hopefully help improve outcomes
in future. Nevertheless, mBC remains a treatable but incurable
disease.
The main goals of mBC treatment are prolongation of life and
symptom palliation [12e14]. Following diagnosis, median survival
is approximately 2e3 years [2,6], and the relative 5-year survival
rate for distant metastatic disease is only 28% compared with 99%
and 86% for localized and regional disease, respectively [7]. In
addition, the quality of life of people with mBC has only minimally
improved in recent years [2,15]. Therefore, mBC represents an area
of high unmet need and is a significant global health burden.
Although several new treatments for mBC have been recently
introduced [12e14,16], positive outcomes depend not only on the
response to treatment, which varies according to disease and pa-
tient characteristics, but also on access to those treatments, which
is affected by a host of factors. The wide variation in these factors
leads to disparities in cancer care between and within countries,
including high-income countries, and not all patients benefit
equally from the healthcare services available [17e26]. For
example, registry data from New Zealand found that the median
survival after mBC diagnosis was 18.8 months (2010e2015), around
half that of other developed countries [27]. Similarly, there are80significant differences in both BC incidence and mortality between
European countries [1,28], and regionally within each country.
Disparities in cancer care can be classified as individual-related
(e.g. age, socioeconomic status, etc.) or system-related (e.g. reim-
bursement, policy, etc.) (Fig. 1).
Individual-related disparities, such as race [30], socioeconomic
status [31,32], and social and psychological factors [33] are well
known to adversely affect patient outcomes.
System-related disparities include significant gaps in mBC-
specific reporting and data collection, cancer care policies,
including access to supportive care services, and healthcare pro-
vider education [15,18,24,26,34e36], as well as barriers in access to
treatments, such as systemic therapies and radiation therapy
[18,37,38]. Intra-country disparities also exist, with geographical
location playing a major part in access to appropriate healthcare
services, such as women in the UK experiencing “postcode pre-
scribing”, resulting in variable access to medication in different
parts of the country [39]. There also remains a need for a greater
understanding of how mBC affects the family and professional life
Table 1
Key risk factors associated with UPPs in mBC, identified by literature search. *Some
articles reported on more than one risk factor.





Social and psychological factors 35
Barriers to healthcare services (e.g. screening, care support etc.) 33
Physiological and lifestyle factors, including comorbidities 21
Age 21
Access to treatment or disease awareness information 21
Familial and genetic factors 14
Education 9
Requirement for HCP education or training 8
Gender 4
Workplace issues 2
Healthcare resource utilization 2
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them [15,35].
Underserved patient populations (UPP) with mBC may be
defined as less likely to receive quality healthcare owing to the
patient- or system-related factors outlined above. Successful stra-
tegies aimed at reducing disparities and increasing access to
optimal treatment and care must be developed for these UPPs.
To better understand the challenges facing UPPs with mBC, it is
important to get the perspective and input of all stakeholders,
including healthcare professionals (HCPs), patient advocacy group
(PAG) representatives, policy makers, politicians and others. The
challenges not only include access to the right treatment and care,
but also improvements in HCP education, policy-related issues,
support for patients, caregivers and employers, investment in
medical innovations and efficient use of healthcare resources. A
multidisciplinary team approach has been shown to improve pa-
tient care and health outcomes in BC [40], including survival [41].
Therefore, multidisciplinary collaboration can build on existing
initiatives, identify remaining gaps, and develop new actions to
drive access to the appropriate care for patients with unmet needs.
In October 2019, a multidisciplinary group of European experts
met in Brussels, Belgium to discuss the access barriers to healthcare
facing UPPs with mBC. Their goal was to conceive and prioritize
actionable solutions that countries and healthcare systems can
implement with multifunctional stakeholder groups, according to
local needs. In this review, we discuss the outcomes and implica-
tions of this debate.
2. Materials and methods
Prior to the meeting, a literature search was conducted to
identify the main risk factors associated with the UPPs in mBC and
define categories of unmet needs. The electronic database, PubMed,
was used to identify relevant English language articles, with filters
employed to limit studies to those in humans and published within
the last five years. Search terms included “breast cancer” AND
(“underserved” OR “disparity” OR “barrier” OR “unmet need” OR
“under resourced” OR “inequality”). Additional studies were iden-
tified through searching key cancer and think-tank institution
websites. All types of publications, including reviews, clinical trials,
white papers and consensus statements were considered. In order
to provide a more accurate picture of the total volume of evidence
pertaining to UPP with BC, the literature search was not limited to
mBC or to Europe.
The findings of the literature search were supported by insights,
gathered through a premeeting survey of attendees, about how
UPPs with mBC are defined in different countries, the priority areas
to address and existing best practices.
The meeting in Brussels was attended by principal European
stakeholders in mBC (“the Expert Panel”), including 10 clinicians
(oncologists), 4 PAG representatives, 2 (ex)payers, a nurse, a psy-
chologist, a politician, a policy affairs manager, and the Managing
Coordinator of the ABC Global Alliance. A series of
multidisciplinary-group workshops were conducted to identify the
key challenges faced by UPPs and develop tangible solutions, which
were explored inmore detail before being subjected towider group
discussion to refine the ideas developed.
3. Results
The literature searches yielded 364 articles that met the search
criteria. After examination of study abstracts, 45 were deemed not
relevant for various reasons (not specific to BC, duplicates, non
patient-centric, theoretical modeling tools, conceptual frame-
works). The remaining 319 articles were categorized according to81the main risk factor(s) reported (Table 1).
The literature searches were supported by the insights gathered
through the survey (Appendix A), which was completed by 15 re-
spondents who identified the key characteristics of UPPs in mBC
(Fig. 2.).
Based on the outputs of the literature search and survey, chal-
lenges identified were grouped according to the following cate-
gories: socioeconomic and workplace issues, education and
awareness needs, healthcare availability and access, and ethnicity
and cultural issues. During workshop discussions, different groups
of experts identified and prioritized multiple challenges associated
with UPPswithmBC and classified them according to the categories
above (Appendix B). The six challenges identified as the most
feasible to address were as follows:
1. Need for improved awareness and amplification of the mBC
voice
2. Better and wider implementation of high-quality guidelines for
mBC
3. Need for improved mBC understanding in non-oncologists and
better communication between primary care physicians (PCPs),
oncologists and patients
4. Need for improved awareness of and tailored approaches to
support patients with mBC in multicultural communities
5. Need for improved mBC data gathering and clinical trials
6. Issues within the workplace
Each of these challenges was debated, and potential solutions
involving all stakeholders were proposed and developed during the
meeting. The proposals are discussed below and summarized in
Table 2.
3.1. Need for improved awareness and amplification of the mBC
voice
One of the greatest needs associated with mBC is raising
awareness of the disease among all stakeholders (patients; patient
advocates; payers; HCPs, including students; policy makers; poli-
ticians; cancer charities; research funding bodies such as the Eu-
ropean Union [EU] and the public). Improved awareness leads to
better understanding and communication across stakeholder
groups and facilitates best-practice sharing. A number of existing
initiatives already work to raise awareness of mBC, including in-
ternational organizations, such as ABC Global Alliance, Union for
International Cancer Control, the Metastatic Breast Cancer Alliance
and several others, as well as national schemes (e.g. the UK
Fig. 2. Most frequently identified UPP characteristics for patients with mBC according
to premeeting survey. “Other” characteristics comprised the following: attitude/cul-
ture of healthcare staff; health system characteristics; quality control; poor informa-
tion; living on an island; diagnosis in young women with related issues, such as
fertility, childcare and work.
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1310 in France, and the German Cancer 10-year plan, to name a
few).
The Expert Panel discussed additional ways in which to raise
awareness and felt that two main channels of communication
would be most effective: an HCP exchange program and an evi-
dence package.
The European Community Action Scheme for the Mobility of
University Students (ERASMUS), is a program established in 1987
by the EU that allows students to study at universities in the EU
member states, EU candidate countries and European Free Trade
Association/European Economic Area members for set periods of
time [42,43]. Since then it has given 6 million students the op-
portunity to spend part of their university career in another country
while achieving credit for their degree at home [43]. ERASMUS
PLUS is a branch of ERASMUS started in 2014 which targets a
broader scope of individuals, including specialized staff, teachers,
trainees, volunteers, and more. ERASMUS PLUS is an invaluable
learning and training experience, and therefore promoting it
among HCPs treating mBC as well as easing the access and securing
adequate grants for this group would give individuals an oppor-
tunity to experience different healthcare systems and allow them
to learn and bring home ideas that could improve their own
practice, similarly to how ERASMUS helps medical students
broaden their intellectual horizons [43]. This move would promote
mBC awareness in two ways. Firstly, it should be expected that a
HCP who has had the opportunity to treat patients and engage in
other healthcare systems will be able to educate their colleagues
back home, as sessions could be held during which HCPs who
attended the program gather to discuss their observations with
other HCPs. Secondly, the HCP will have a better understanding of
patients from different backgrounds, will be more culturally sen-
sitive, and will know better how to approach them. This could help
support continuous HCP education and facilitate information and
best practice sharing across European countries, in line with wider-
reaching initiatives such as comparative data sharing (see also “3.5
Need for improved mBC data gathering” below). This initiative
would be targeted towards nurses, physicians, physiotherapists,
psycho-oncologists, palliative care professionals, social workers
and other allied HCPs across Europe, with political level support,
such as funding from the EU.
The Expert Panel also proposed an “evidence package” of stan-
dardized data to identify and validate challenges and unmet needs
faced by patients with mBC in a particular country. This would be
targeted towards national politicians, providing consistent infor-
mation to support governments in raising awareness of mBC and
addressing challenges and offering a starting point from which to82identify the greatest priorities for healthcare resources, in line with
pan-European initiatives such as the “Europe Beating Cancer” Plan,
which aims to reduce the burden of cancer and address cancer-
related inequalities between countries [44], and National Cancer
Control Program (NCCPs) that are designed to improve all cancer
care in individual countries through evidence-based strategies [45].
The evidence package could also be used by other stakeholders,
such as physicians, nurses and other HCPs, to lobby for change. The
first step would be to gather accurate and up-to-date statistics (see
also “3.5 Need for improved mBC data gathering” below),
beginning with national cancer registries and other sources of
objective information. To implement such an initiative would
require funding for gathering evidence (data collecting, analysis,
and reporting) and creating action plans. The evidence would
require evaluation by multiple stakeholders, such as HCPs and
policymakers.
3.2. Better and wider implementation of high-quality guidelines for
mBC
There are international evidence-based guidelines specific to
the treatment of mBC [12,13,16] and specialist nurse support [46] as
well as many individual country-specific guidelines, but these are
not always faithfully implemented in practice [47e49]. Since cancer
plans are not universal throughout Europe, the European Com-
mission has decided to develop an inclusive ‘‘Europe Beating Can-
cer’’ plan for all EU members, which would provide standards for
therapy planning and management [44].
The Expert Panel felt that the empowerment and education of
patients, through the support of PAGs, including bodies like the
European Cancer Patient Coalition, could compel physicians to treat
according to high-quality guidelines, thereby increasing their
widespread implementation. Themore educated patients are about
their treatment options, the more likely they are to discuss guide-
lines and recommended treatments with their HCPs, primarily
oncologists, encouraging them to treat according to the guidelines.
It is thought that many patients are afraid to challenge HCPs and
ask about guidelines, so their empowerment should initially come
from PAGs (provided they are without any financial conflicts of
interest), before translating to the individual patient. Patients
should also be entitled to rely on the expertise of an HCP who is
fully aware and compliant with certified and validated national
guidelines, something that should be included in HCP training
initiatives. This could be actively supported by European cancer
organizations, such as the European School of Oncology and the
European Society for Medical Oncology (ESMO), in addition to na-
tional professional organizations that provide national guidelines
adapted to each country’s reality. This may ultimately facilitate
national access to specific treatments and care modalities. Guide-
line implementation could be monitored by national cancer regis-
tries through regular surveys of the stakeholders, documenting
treatments that are guideline-compliant, although anonymity of
individuals would need to be guaranteed in order to get an accurate
picture, since there are often instances where guidelines are not
followed due to external factors, such as financial reasons. Alter-
natively, information could be sourced from existing databases,
real-world data projects and/or market research, which would
involve considerable effort, but would yield important intelligence.
Utilizing data to enable individual HCPs to see how they would
compare with the national average could also be useful to promote
good practice. This proposal would also align with the ECC’s Eu-
ropean Cancer Patient’s Bill of Rights, which advocates a patient-
centric approach to cancer care, including every patient’s right to
receive the most accurate information and to be proactively
involved in their own care [50, 51].
Table 2
Summary of the potential actionable goals and their main requirements to address the six main challenges in access to care for the UPPs with mBC. *This initiative would not work in Belgium since specialists play the role of GPs
for these patients owing to resource constraints and the way the patient pathway is structured. BC, breast cancer; BCN, Breast Cancer Now; EU, European Union; GP, general practitioner; HCP, healthcare professional; HRU,
healthcare resource utilization; mBC, metastatic breast cancer; PAG, Patient Advocacy Group; QoL, quality of life; UPP, underserved patient population.
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better communication between PCPs, oncologists and patients
A holistic approach to treating mBC involves a variety of HCPs.
PCPs have an important role in the care of patients with BC, since
they can be the initial point of contact for the first presentation of
BC symptoms, symptoms of relapse, for the management of long-
term side effects after cancer treatment or comorbidities, and for
screening psychosocial needs for appropriate referral [34,52e54].
Skilled PCPs could provide support throughout therapy, particularly
in areas or centers that may not have extensive multidisciplinary
support teams to manage specific comorbidities. Many patients
with cancer have concerns about seeing their PCP for cancer-
related follow-up care [54,55]. Therefore, clear guidance is
needed on the respective roles of the PCP, the home nurse, and the
pharmacist, with a need to drive coordination and communication
between the oncologist and PCPs. Some such initiatives are
currently in existence. For example, in the UK, Macmillan has
produced toolkits, guidance documents, and online training to
support PCPs in connecting with patients with cancer. There is also
an e-learning community to provide cancer-specific educational
opportunities for registered nurses.
Successful HCP-patient (and caregiver) communication in the
advanced cancer setting helps patients come to terms with their
disease and its treatment, cope with the impact on their lives, and
may help to improve clinical outcomes [56,57]. Understanding and
addressing patients’ concerns, needs and preferences requires
effective communication skills, which has been recognized as an
area for improvement in medical education and clinical care. Rec-
ommendations for HCP communication skills training and clinical
practice guidelines for its implementation have been made [58,59].
Another potential improvement is the greater use of patient-
reported outcomes (PROs). PROs can enhance physician and nurse
understanding of patient symptoms and the impact they have on
quality of life, thereby facilitating a more tailored approach to
clinical decision making and reducing service utilization for un-
controlled symptoms [60].
The Expert Panel identified a lack of knowledge of the statistics
of PCP involvement in mBC as a factor affecting HCP resource
management and proposed a pilot scheme to evaluate healthcare
resource utilization before and after a series of small interventions.
These interventions would aim to increase PCP awareness and
understanding of mBC and facilitate communication between pa-
tients, PCPs, and oncologists (Table 2). Enhancing non-oncologist
awareness of the needs of patients with mBC would increase the
time available to oncologists, thereby potentially enabling them to
devotemore time to UPPs. The pilot schemewould require baseline
evaluation of healthcare resource utilization related to non-mBC
follow-up, i.e. management of comorbidities, infections, psycho-
social needs, etc., that could be delivered by non-oncology staff. It
would require the development of a series of small interventions
that support management of oncology-related healthcare. One
intervention could be devising a “red flags for mBC” guide e a
handy reference guide of top tips for busy PCPs, which could pro-
vide helpful advice on how tomanage patients withmBC andwhen
to seek specialist care, with a focus on “red flag situations” in
follow-up after early BC and in management of mBC. Another
intervention could be promoting patient education on how to
effectively communicate with non-oncologists (“What do I need to
tell my PCP about my cancer?“); available commercial apps like the
multilingual, Cankado, could be utilized. Finally, a third interven-
tion would aim to connect oncologists and PCPs who care for the
same patient, to improve communication channels between them.
The effect of all the interventions on healthcare resource utilization
in the pilot center would ideally be measured one year after85implementation and, if successful, the scheme could be rolled out
nationally.
3.4. Need for improved awareness of and tailored approaches to
support patients with mBC in multicultural communities
Racial disparities in BC care are well documented [61,62]. For
example, black women are more likely to die of BC than white
women [62]. Black women are also significantly less likely to
receive cancer-directed surgery, radiation therapy, and hormonal
therapy, are underrepresented in clinical trials, and have poorer
access to trial-based innovations in cancer care compared with
white women [61,62]. Other cultural and socioeconomic differ-
ences also exist. For example, immigrant and low-income women
living in Switzerland were less likely to take up BC-preventative
methods, such as mammography and breast self-examination,
compared with Swiss nationals [63]. Another study showed the
general trend of lower breast screening uptake in immigrant
women in Italy compared with Italian women between 2005 and
2013. However, it also showed that the prevalence of breast
screening is higher among immigrant women in Northern Italy
than among Italian women in Southern Italy [64]. In general,
migrant women are more likely to utilize emergency health ser-
vices than non-migrants [65], which is likely related to low rates of
acculturation [66]. Lack of awareness and misrepresentation may
also affect the lesbian, gay, bisexual and transgender community
and there is a need for improved appropriate social support for
sexual and gender minority BC survivors [67].
Every European patient should have the right to optimal and
timely access to appropriate specialized care [50,51]. Evaluation of
subpopulations in each region is required to understandwhere best
to focus efforts and identify those patient groups that need support
(e.g. cultures, ethnicities, ages, sexual orientations, migrants and
traveling communities), although this may be limited by data
protection laws in some countries. There is also the need to
approach any intervention in a culturally sensitive and appropriate
manner.
The Expert Panel suggested targeting community-based peer
groups and HCPs embedded in communities to collect data and
create tailored education on mBC. This would include information
on how to appropriately refer to the disease and patients’ needs
within the medical communities that serve these subpopulations,
help with language/socioeconomic issues, and to create and verify
information to support local UPPs (Table 2). Local PAGs, cultural
organizations, and community-based HCPs should identify existing
local communities and projects at a grass roots level, to advise on
the content of new initiatives aiming to tackle health-related
problems. Many cultural community projects already exist, for
example the Breast Cancer Project by Race Equality Foundation or
the MOPA (Muslim and Palliative Care Antwerp) and similar ini-
tiatives by Kom op tegen Kanker in Belgium, which provides
culturally-tailored guidance to Muslim cancer patients requiring
palliative care and their families, and engages with Muslim clerics
to help disseminate appropriate messages to the community
through the mosques. Initiatives such as these can help provide the
appropriate knowledge and insight needed to address the dispar-
ities in local underserved mBC populations. The proposed inter-
vention for mBC should encompass minorities with cultural taboos
and/or language barriers and include both men and women. It
would operate at a locoregional level to identify the relevant sub-
populations and their needs and then develop a targeted education
program for specific subpopulations. It would be adapted to
different communities, with different content styles to allow for
language barriers, i.e. visuals rather than words, translation of
content into different languages, etc. This initiativewould be driven
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inform the program, as well as implement local rollout and
encourage the targeted subpopulation(s) to get involved. Further
considerations would include involvement of local educational
establishments and social security departments for further infor-
mation gathering, and support in rolling out local initiatives.
3.5. Need for improved mBC data gathering and clinical trials
There are evident data gaps in the recording of mBC statistics.
There are very few accurate records of the number of people who
are living with mBC, how many patients with early-stage BC have
recurrences, and how the incidence and outcome of mBC have
changed over time for the common subtypes of BC [2, 4e6].
Furthermore, cancer registration in Europe is challenged by sig-
nificant disparities in the quality and coverage of cancer registries
[68], while some countries do not have a cancer registry at all.
Although several groups in different countries are working to
improve data collection, further work is clearly needed. Primary
data-generation needs of mBC management identified by the
Expert Panel include the creation of registries where they do not
yet exist; active sharing of resources and real-world data between
BC clinics; the introduction of biorepositories for studies to identify
biomarkers for treatment response. There is also a need to recon-
sider the approach to conducting mBC clinical trials, making them
more sustainable and more efficient in terms of data generation
[69]. Considering the aforementioned disparities between coun-
tries affecting the quality and consistency of the reported data, it
seems plausible from the perspective of the local health authority
that making investments in trial innovation, such as increasing the
expenditures going into mBC research and strengthening ties with
global academia and industry, and promoting transparency in
collection and reporting of trial data could improve both sustain-
ability and efficacy of the trials. It would also heighten the country’s
reputation for research capacity and promote research globaliza-
tion and quality.
The preferred solution discussed by the Expert Panel was to
create a platform where accurate capturing of mBC data across
Europe would be the main goal (Table 2). The scheme would
leverage existing registries to improve what already exists by
examining current examples of good practice and working with
pan-European and international organizations such as EUROCARE,
AROME, or IARC in Lyon, France. Other ideas discussed included
introducing an outcome measure by the ESMO, and an annual mBC
census where the government compels centers to collect up-to-
date data on metastatic disease.
Clinical trials have resulted in significant advances in many as-
pects of BC care, for example as a way of offering emerging new
therapies to patients [24]. Furthermore, there is some evidence to
suggest that access to clinical trials is associated with improved
survival for mBC patients [70]. Clinical trial information is, rightly,
aimed primarily at oncologists, but should also be publicly acces-
sible through national/regional databases (e.g. as it is via cancer-
trials.be in Belgium). However, although the Expert Panel
acknowledged the need for greater awareness of and improved
access to clinical trials for mBC patients, potential measures to
address this were not discussed at the meeting.
3.6. Issues within the workplace
Many patients with cancer want to return to work in order to
attain a sense of normality, to maintain a positive outlook and for
financial reasons. A survey byMacmillan in the UK showed that 87%
of employed people diagnosed with cancer said that it was
important to them to continue working [71]. However, the same86survey also showed that patients need support to return to work
following a cancer diagnosis, with one in five facing discrimination
at work. In some countries, legal measures protect the employment
rights of cancer patients. For example, in the UK, cancer is
considered as a disability under Equality Act 2010, meaning that an
employee cannot lose their job or be treated less favorably for
having cancer, yet many employers remain unaware of this [72]. In
addition, many employers need advice and training to help them
support employees with cancer. The Macmillan survey found that
only one-third of line managers feel well equipped to support
employees with cancer [71]. Caregivers are also affected. In the UK,
caregivers have the right to request flexible working and emer-
gency time off for dependents and are protected against discrimi-
nation. Caregivers in Germany are entitled to similar privileges
under the Pflegejahr scheme.
Both the Macmillan at Work scheme and Barbara Wilson’s
Working with Cancer® in the UK support employees and em-
ployers, by providing a range of services including advice and in-
formation, toolkits and e-learning modules, newsletters, best
practice guides, coaching sessions and consultancy advice.
Similar initiatives to support employers across Europe could be
introduced. The preferred and most feasible solution identified by
the Expert Panel was a ‘Seal of Approval’ accreditation scheme that
creates a supportive work environment for patients with mBC and
their caregivers (Table 2). The scheme, which realistically would
cover all cancers, not just mBC, would target workplaces and em-
ployers to encourage the establishment of a cancer-friendly work
environment for patients and caregivers, with benefits such as
flexible working hours, guidance for managers, and tax or social
security benefits for the employee. This would be a national-level
initiative and could start with a pilot scheme involving the state
(as the largest employer) setting an example, with other major
businesses being part of the pilot. The pilot scheme would collect
evidence to ensure that this is a workable idea, e.g. by gathering
data on the number of employees affected, and collating informa-
tion on the legal position and outlining the role of different
stakeholders, including managers and human resource pro-
fessionals. A charter or checklist of criteria that workplaces need to
meet would be used to assess workplace qualification for accredi-
tation. If successful, and cost-effective, the scheme could poten-
tially be rolled out to smaller businesses. The scheme should also
consider implications for employers and inform patients of their
legal rights. PAGs would be the main drivers of this initiative.
This type of initiative does come with some limitations, for
example, taking account of disparities in social security and health
care insurance at national level across Europe. There may also be a
need for legislation to flexibly balance social security benefits and
part-time employee salaries (especially if that employer is that
state itself), without an adverse impact on either employee or
employer finances. In fact, the scheme should be financially neutral
(subsidized) for employers with, for example, compensation for the
enhanced administration and cost of hiring two part-time workers
instead of one full-time person. Self-employed workers would also
need to be considered and benefit from equivalent measures.
4. Discussion
Improving outcomes for patients with mBC across Europe, and
indeed the world, remains one of the biggest healthcare challenges
in oncology. Mortality rates for metastatic disease remain high, so,
from a certain point of view, all patients with mBC could be
considered underserved. However, for those patients that are un-
derserved owing to either individual factors, such as age, ethnicity,
socioeconomic status and others, and/or persistent disparities in
cancer care, the unmet needs are even greater. Nevertheless, these
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tions, such as the ABC Global Alliance, the mBC Alliance, the EU and
may other national or local organizations and initiatives, who are
striving to develop, promote and support raising awareness,
sharing best practices and, hopefully, addressing the specific needs
of UPPs to ultimately improve and extend the lives of those living
with mBC.
Working to these same goals, the Expert Panel identified and
prioritized six key challenges that could feasibly be addressed in
order to improve the situation of UPPs with mBC in Europe. They
then conceived proposals and ideas that could most readily be
developed and measured by multi-stakeholder groups and au-
thorities to address those challenges. This included raising aware-
ness of the mBC voice, better and wider implementation of mBC
guidelines, improved cooperation between the different HCPs,
adequate tailoring of support, enhancing local and international
data exchange, and tackling issues faced in the workplace.
Taken individually, each of the proposals outlined above should
be considered a starting point for individual countries to review
and assess the impact of existing initiatives and either build on
them or establish something new, based on the ideas presented
here. Given the importance of multidisciplinary stakeholder
participation to ensure a holistic approach to any of these projects,
it is recommended that each country should utilize (or convene, if
one is not already in existence) a “National Multidisciplinary mBC
Working Group” to be responsible for the supervision, manage-
ment and measurement of the impact of any actions undertaken.
These national working groups could then partner with each other,
as well as with existent multinational organizations, specifically the
ABC Global Alliance, to move towards a pan-European approach to
tackling these challenges. mBC working groups should also operate
in harmony with wider cancer care initiatives, including NCCPs and
the European Cancer Patient’s Bill of Rights.
It is important to see how the proposals outlined in this review
are interrelated, to examine the role of and benefits to the different
stakeholders, as well as considering how they could be imple-
mented and assessed for effectiveness.
Raising public awareness of the mBC voice, through initiatives
such as the evidence package and the work accreditation scheme,
would improve the representation of this group in society. Pro-
moting the mBC voice locally means it would be heard in national
political circles, potentially leading to development of laws and
policies that would benefit patients, caregivers, employers and
healthcare providers.
An organized and principled HCP education system that bal-
ances robust scientific evidence, a compassionate approach to
treatment, economically viable practices and effective communi-
cation between all stakeholders is key for providing effective care.
Therefore, ensuring implementation of high-quality mBC treat-
ment guidelines in all countries, driven by patient empowerment,
coupled with targeted HCP training and interventions to support
management of non-oncology-related healthcare, would both
assure a more consistent treatment approach and facilitate
appropriate dialogue between patients, oncologists, PCPs and other
HCPs for enhanced understanding and shared treatment decision
making. To implement these measures, establishment of local pa-
tient education groups, in which patients would be able liaise with
local HCPs to learn about and discuss treatment guidelines and
available treatments, would be encouraged.
However, healthcare education and implementation of guide-
lines should consider the multicultural and diverse nature of the
modern population inhabiting Europe. Patients with mBC
belonging to different cultures, subcultures and societal groups87require an individualized approach. Therefore, stakeholders,
including HCPs, social workers and politicians, should work with
representatives of each subpopulation to ensure that the right
support is available to everyone regardless of their culture,
ethnicity, creed, level of acculturation and/or sexual orientation.
Finally, HCPs are at the center of healthcare and by providing
them with best resources and educational opportunities available,
the authorities can ensure the best level of care. Implementation of
guidelines, promoting the mBC voice and educating PCPs could
help HCPs who provide oncology services to perform better. Un-
derpinning this is the need to capture a comprehensive and accu-
rate picture of the scope of the mBC population in each country,
through national registries and real-world data collection.
Furthermore, this, coupled with the proposed mBC HCP exchange
program, would broaden the international cooperation on mBC
treatment, allowing HCPs to make better-informed decisions and
have a stronger understanding of the current clinical landscape.
5. Conclusions
The challenges faced by UPPs with mBC are wide-ranging and
varied and, therefore, addressing them successfully requires a co-
ordinated, multidisciplinary approach that involves all stake-
holders, from patients to politicians. The disparities that exist
across Europe must be tackled by cooperation and collaboration
both within and between countries. Effective interventions must
focus not only on the patients but also address the system, to
improve care across the continuum of mBC evaluation and treat-
ment.We have highlighted some of the high priority access barriers
to healthcare facing UPPs with mBC and suggest actionable goals
that countries and health systems can aim to implement through
multifunctional stakeholder groups, in accordance with local needs
and in synergy with existing initiatives. It is hoped that this could
encourage a move towards building a revised approach to the
treatment and care of one of the biggest burdens on women’s
health in the 21st century.
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Appendix A. Premeeting survey questions and key findings
Survey questions
1. How would you describe the characteristics of underserved
patient populations with breast cancer in your country? Please tick
any of the factors below that you feel represent this population:
 Low socio-economic status
 Low levels of education
 Low levels of health literacy/access to information88 Geography
o Located in a rural setting and/or area with poor transport
infrastructure
o Located in an area where access to services is poor
 Ethnicity/culture




 Suffer from comorbidities including mental health
 Workplace issues
 Other e please specify
2. Are any of these factors particularly relevant to patients with
metastatic breast cancer? If yes, please outline which ones.
3. What are the biggest unmet needs for underserved patient
populations with metastatic breast cancer?
4.What are the challenges in addressing the unmet needs of the
UPPs in metastatic breast cancer or making these a priority in your
country/the EU?
5. Are you aware of any specific examples such as papers or
initiatives developed to address the UPPs needs inmetastatic breast
cancer? Please specify examples based on the following categories:
 From a policy perspective
 From a clinical perspective
 From a patient/advocacy perspective
Survey responses
The principal unmet needs identified by the survey for the UPP
with mBC were:
 Better treatments, including equitable early access to new drugs
 Access to quality specialized care (e.g. mBC-specific guidelines,
early diagnosis, culturally sensitive care), especially a clinical
specialist team with good communication skills
 Access to disease and treatment information, including clinical
trial recruitment
 Psychological/emotional support
oGreater recognition of mBC and its impact (not just on pa-
tients but also on their caregivers and employers) at a na-
tional level (e.g. mBC Awareness Day)The challenges in addressing the unmet needs of the UPPs in
mBC or in making these a priority identified by the survey were:
 A need for more multidisciplinary teams, incorporating psy-
chologists, nutritionists, specialist nurses and community-based
HCPs, as well as more specialist breast units and referral centers
 A need for better communication between HCPs and patients
and a greater understanding of the needs of diverse cultural
populations by physicians
 There is a lack of adequate cancer-control policies, and a need
for more action by politicians to highlight the burden of mBC
and promote initiatives to address unmet needs
 Separate systems of governance and ‘postcode lotteries’ within
countries may result in disparities in treatment between
different regions
 There is a bias towards prioritizing messages about early breast
cancer over metastatic disease in many national awareness
campaigns (e.g. Pink October)
Appendix B
Challenges associated with mBC UPPs identified during the workshops at the expert meeting
Category Group 1 Group 2 Group 3
Healthcare availability and access Lack of access to integrated and
specialized care for patients
with BC.
Lack of trained medical staff
dedicated to cancer care.
Lack of specialists (and
education of) with an interest in
mBC.
Access to treatments. Lack of early access to
treatments.




Need for improved access to
clinical trials.
Lack of data and registries e no
accurate counting of patients
with mBC.
Access to diagnosis and genetic
testing.
Access in rural locations.
Education and awareness needs Lack of training and knowledge
of citizens.
Lack of awareness of mBC. Lack of mBC awareness.
Lack of knowledge of and access
to existing clinical trials.




Lack of focus on PROs þ QoL. Poor workplace understanding.
Better physicianepatient
communication.
Ethnicity and cultural issues Need for better communication
between HCPs and patients.
Access to clinical trials for
broader ethnic groups.
Age discrimination.
Religious and cultural barriers. Lack of understanding of
cultural needs and norms.
Cultural/ethnic minority
challenges.
Mismatch between patient and
HCP perspectives.
Socioeconomic and workplace issues Low socioeconomic status. Socioeconomic status dictates
levels of access to care.
Financial burden.
Social and economic support
and flexible working policies.
Lack of workplace support and
policies.
Including both guidelines and
economic support in national
cancer plans.
Overtreatment of patients.
BC, breast cancer; HCP, healthcare professional; mBC, metastatic breast cancer; PRO, patient-reported outcome; QoL, quality of life; UPP, underserved patient population.
E. Vrdoljak, J. Gligorov, L. Wierinck et al. The Breast 55 (2021) 79e90References
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLO-
BOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
countries. CA A Cancer J Clin 2018;68:394e424.
[2] Cardoso F, Spence D, Mertz S, et al. Global analysis of advanced/metastatic
breast cancer: decade report (2005e2015). Breast 2018;39:131e8.
[3] Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd International Consensus
Guidelines for advanced breast cancer (ABC2). Breast 2014;23:489e502.
[4] Gobbini E, Ezzalfani M, Dieras V, et al. Time trends of overall survival among
metastatic breast cancer patients in the real-life ESME cohort. Eur J Canc
2018;96:17e24.
[5] Fietz T, Tesch H, Rauh J, et al. Palliative systemic therapy and overall survival
of 1,395 patients with advanced breast cancer e results from the prospective
German TMK cohort study. Breast 2017;34:122e30.
[6] Sundquist M, Brudin L, Tejler G. Improved survival in metastatic breast cancer
1985e2016. Breast 2017;31:46e50.
[7] National Cancer Institute. SEER stat fact sheets: female breast cancer. Avail-
able from, http://seer.cancer.gov/statfacts/html/breast.html. [Accessed 6 July
2020].
[8] Hartkopf AD, Huober J, Volz B, et al. Treatment landscape of advanced breast
cancer patients with hormone receptor positive HER2 negative tumors e data
from the German PRAEGNANT breast cancer registry. Breast 2018;37:42e51.
[9] Lux MP, Nabieva N, Hartkopf AD, et al. Therapy landscape in patients with
metastatic HER2-positive breast cancer: data from the PRAEGNANT real-
world breast cancer registry. Cancers 2019;11:10.
[10] McCann KE, Hurvitz SA. Advances in the use of PARP inhibitor therapy for
breast cancer. Drugs Context (US) 2018;7:212540.
[11] Reddy SM, Caroll E, Nanda R. Atezolizumab for the treatment of breast cancer.
Expert Rev Anticancer Ther 2020:1e8.
[12] Cardoso F, Senkus E, Costa A, et al. 4th ESOeESMO international consensus
guidelines for advanced breast cancer (ABC 4). Ann Oncol 2018;29:1634e57.
[13] Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone
receptor-positive metastatic breast cancer: American Society of Clinical
Oncology Guideline. J Clin Oncol 2016;34:3069e103.
[14] Waks AG, Winer EP. Breast cancer treatment: a review. J Am Med Assoc
2019;321:288e300.
[15] Avenda~no C, Benn K, Biganzoli L, et al. A policy roadmap on addressing
metastatic breast cancer. Available from. 2017. https://lillypad.eu/WP/wp-
content/uploads/MBC-Policy-Roadmap-Report-digital-version-17.09.2017.
pdf. [Accessed 6 July 2020].89[16] National Comprehensive Cancer Network. NCCN breast cancer guidelines.
Available from, https://www.nccn.org/professionals/physician_gls/default.
aspx#site. [Accessed 6 July 2020].
[17] Unger-Salda~na K. Challenges to the early diagnosis and treatment of breast
cancer in developing countries. World J Clin Oncol 2014;5:465e77.
[18] European Cancer Patient Coalition (ECPC). Challenging the Europe of Dispar-
ities in Cancer. A framework for improved survival and better quality of life
for European cancer patients. Available from, https://ecpc.org/wp-content/
uploads/2019/08/ECPC-White-Paper-Europe-of-disparities-EN-3.pdf.
[Accessed 6 July 2020].
[19] Dixit N, Crawford G, Lemonde M, et al. Left behind: cancer disparities in the
developed world. Support Care Canc 2016;24:3261e4.
[20] Sullivan R, Aggarwal A. Putting a price on cancer. Nat Rev Clin Oncol 2016;13:
137e8.
[21] Byrne J, Capbell H, Gilchrist M, et al. Barriers to care for breast cancer: a
qualitative study in Ireland. Eur J Canc Care 2017;27:e12876.
[22] Ginsburg O, Bray F, Coleman MP, et al. The global burden of women’s cancers:
an unmet grand challenge in global health. Lancet 2017;389:847e60.
[23] Dean LT, Gehlert S, Neuhouser ML, et al. Social factors matter in cancer risk
and survivorship. Cancer Causes Control 2018;29:611e8.
[24] Thrift-Perry M, Cabanes A, Cardoso F, et al. Global analysis of metastatic breast
cancer policy gaps and advocacy efforts across the patient journey. Breast
2018;41:93e106.
[25] Boyce K, White C, Hunt P, et al. Inequalities in health? An update on the effect
of social deprivation for patients with breast cancer in South East Wales.
Surgeon 2019;17:88e96.
[26] Ren J-X, Gong Y, Ling H, et al. Racial/ethnic differences in the outcomes of
patients with metastatic breast cancer: contributions of demographic, socio-
economic, tumor and metastatic characteristics. Breast Canc Res Treat
2019;173:225e37.
[27] Breast Cancer Foundation New Zealand (BCFNZ). “I’m still here”. Insights into
living - and dying e with advanced breast cancer in New Zealand. Available
from, https://breastcancerfoundation.org.nz/Images/Assets/21894/1/BCFNZ-
ABC-Report-2018-Executive-Summary.pdf. [Accessed 6 July 2020].
[28] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer
survival 2000e14 (CONCORD-3): analysis of individual records for 37513 025
patients diagnosed with one of 18 cancers from 322 population-based reg-
istries in 71 countries. Lancet 2018;391:1023e75.
[29] Vrdoljak E, Bodoky G, Jassem J, et al. Cancer control in Central and Eastern
Europe: current situation and recommendations for improvement. Oncol
2016;21:1183e90.
E. Vrdoljak, J. Gligorov, L. Wierinck et al. The Breast 55 (2021) 79e90[30] Yedjou CG, Sims JN, Miele L, et al. Health and racial disparity in breast cancer.
Adv Exp Med Biol 2019;1152:31e49.
[31] Lyle G, Hendrie GA, Hendrie D. Understanding the effects of socioeconomic
status along the breast cancer continuum in Australian women: a systematic
review of evidence. Int J Equity Health 2017;16:182.
[32] Dreyer MS, Nattinger AB, McGinley EL, et al. Socioeconomic status and breast
cancer treatment. Breast Canc Res Treat 2018;167:1e8.
[33] Teo I, Vilardaga JP, Tan YP, et al. A feasible and acceptable multicultural
psychosocial intervention targeting symptom management in the context of
advanced breast cancer. Psycho Oncol 2020;29:389e97.
[34] Travado L, Reis JC, Watson M, et al. Psychosocial oncology care resources in
Europe: a study under the European partnership for action against cancer
(EPAAC). Psycho Oncol 2017;26:523e30.
[35] European Cancer Patient Coalition (ECPC). Transforming Breast Cancer
Together. White paper on a new collaborative initiative to improve breast
cancer prevention, diagnosis and care across Europe. Available from, https://
ecpc.org/wp-content/uploads/2019/08/ecpc-white-paper-transforming-
breast-cancer-together-2.pdf. [Accessed 6 July 2020].
[36] ABC Global Charter. Available from, https://www.abcglobalalliance.org/abc-
global-charter/. [Accessed 6 July 2020].
[37] Atun R, Jaffray DA, Barton MB, et al. Expanding global access to radiotherapy.
Lancet Oncol 2015;16:1153e86.
[38] Economist Intelligence Unit (EIU) and European Society for Medical Oncology
(ESMO). Cancer medicines shortages in Europe. Policy recommendations to
prevent and manage shortages. Available from, http://www.eiu.com/graphics/
marketing/pdf/ESMO-Cancer-medicines-shortages.pdf. [Accessed 6 July
2020].
[39] All-Party Parliamentary Group on Breast Cancer. A mixed picture: an inquiry
into geographical inequalities and breast cancer breast. Available from,
https://breastcancernow.org/sites/default/files/appgbc_a_mixed_picture.pdf.
[Accessed 6 July 2020].
[40] Blackwood O, Deb R. Multidisciplinary team approach in breast cancer care:
benefits and challenges. Indian J Pathol Microbiol 2020;63(Supplement):
S105e12.
[41] Kesson EM, Allardice GM, George WD, et al. Effects of multidisciplinary team
working on breast cancer survival: retrospective, comparative, interventional
cohort study of 13 722 women. BMJ 2012;344:e2718.
[42] European Funding Guide. Requirements to join the Erasmus Programme.
Available from. 2015. http://www.european-funding-guide.eu/articles/
financing-tips/requirements-join-erasmus-programme. [Accessed 6 July
2020].
[43] Corr M. So you want to be an erasmus medical student? Ulster Med J 2016;85:
60e1.
[44] European Commission. Europe’s beating cancer plan. Available from, https://
ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12154-
Europe-s-Beating-Cancer-Plan. [Accessed 28 August 2020].
[45] Jelenc M, Albreht T, Budewig K, et al. Cancer control joint action. European
guide on quality improvement in comprehensive cancer control. Policy paper
on national cancer control programmes (NCCPs). Available from, https://
cancercontrol.eu/archived/uploads/PolicyPapers27032017/Policy_Paper_2_
NCCP.pdf. [Accessed 28 August 2020].
[46] Eicher M, Kadmon I, Claassen S, et al. Training breast care nurses throughout
Europe: the EONS post-basic curriculum for breast cancer nursing. Eur J Canc
2012;48:1257e62.
[47] Bechold R. How do I say this nicely? Your oncologist wasn’t following
guidelines. Cancer Network. March 26, 2013. Available from, https://www.
cancernetwork.com/blog/how-do-i-say-nicely-your-oncologist-wasnt-
following-guidelines. [Accessed 6 July 2020].
[48] Andre F, Neven P, Marinsek N, et al. Disease management patterns for post-
menopausal women in Europe with hormone-receptor-positive, human
epidermal growth factor receptor-2 negative advanced breast cancer. Curr
Med Res Opin 2014;30:1007e16.
[49] Boskovic L, Gasparic M, Petkovic M, et al. Bone health and adherence to
vitamin D and calcium therapy in early breast cancer patients on endocrine
therapy with aromatase inhibitors. Breast 2017;31:16e9.90[50] Lawler M, Le Chevalier T, Murphy Jr MJ, et al. A catalyst for change : the
European cancer patient’s Bill of rights. Oncol 2014;19:217e24.
[51] Lawler M, Banks I, Law K, et al. The European cancer patient’s Bill of rights,
update and implementation 2016. ESMO Open 2016;1:e000127.
[52] Klabunde CN, Ambs A, Keating NL, et al. The role of primary care physicians in
cancer care. J Gen Intern Med 2009;24:1029e36.
[53] Hamilton W, Barrett J, Stapley S, et al. Clinical features of metastatic cancer in
primary care: a caseecontrol study using medical records. Br J Gen Pract
2015:e516. https://doi.org/10.3399/bjgp15X686077.
[54] Wallner LP, Li Y, Furgal AKC, et al. Patient preferences for primary care pro-
vider roles in breast cancer survivorship care. J Clin Oncol 2017;35:2942e8.
[55] Hudson SV, Miller SM, Hemler J, et al. Adult cancer survivors discuss follow-up
in primary care: “not what I want, but maybe what I need”. Ann Fam Med
2012;10:418e27.
[56] Epstein RM, Street Jr RL. Patient-centered communication in cancer care:
promoting healing and reducing suffering. Bethesda, MD: National Cancer
Institute, NIH Publication No. 07-6225; 2007.
[57] Thomssen C, Lüftner D, Untch M, et al. International consensus conference for
advanced breast cancer, Lisbon 2019: ABC5 Consensus e assessment by a
German Group of Experts. Breast Care 2020;15:82e95.
[58] Clayton JM, Hancock KM, Butow PN, et al. Clinical practice guidelines for
communicating prognosis and end-of-life issues with adults in the advanced
stages of a life-limiting illness, and their caregivers. Med J Aust 2007;186:
S77e105.
[59] Gilligan T, Coyle N, Frankel RM, et al. Patient-clinician communication:
American society of clinical oncology consensus guideline. J Clin Oncol
2017;35:3618e32.
[60] Stover AM, Tompkins Stricker C, Hammelef K, et al. Using stakeholder
engagement to overcome barriers to implementing patient-reported out-
comes (PROs) in cancer care delivery. Med Care 2019;57:S92e9.
[61] Wheeler SB, Reeder-Hayes KE, Carey LA. Disparities in breast cancer treatment
and outcomes: biological, social, and health system determinants and op-
portunities for research. Oncol 2013;18:986.
[62] Reeder-Hayes KE, Anderson BO. Breast cancer disparities at home and abroad:
a review of the challenges and opportunities for system-level change. Clin
Canc Res 2017;23:2655e64.
[63] Fontana F, Bischoff A. Uptake of breast cancer screening measures among
immigrant and Swiss women in Switzerland. Swiss Med Wkly 2008;138:
752e8.
[64] Francovich L, Di Napoli A, Rossi PG, et al. Cervical and breast cancer screening
among immigrant women resident in Italy [Article in Italian]. Epidemiol Prev
2017;41(3e4 Suppl 1):18e25.
[65] Graetz V, Rechel B, Groot W, et al. Utilization of health care services by mi-
grants in Europe - a systematic literature review. Br Med Bull 2017;121:5e18.
[66] Schwachenwalde S, Sauzet O, Razum O, et al. The role of acculturation in
migrants’ use of gynecologic emergency departments. Int J Gynecol Obstet
2020;149:24e30.
[67] Brown MT, McElroy JA. Unmet support needs of sexual and gender minority
breast cancer survivors. Support Care Canc 2018;26:1189e96.
[68] Forsea AM. Cancer registries in Europe-going forward is the only option.
Ecancermedicalscience 2016;10:641.
[69] Flowers M, Birkey Reffey S, Mertz SA, et al. Obstacles, opportunities and pri-
orities for advancing metastatic breast cancer research. Canc Res 2017;77:
3386e90.
[70] Lee JY, Lim SH, Lee M-Y, et al. The impacts of inclusion in clinical trials on
outcomes among patients with metastatic breast cancer (MBC). PloS One
2016;11:e0149.
[71] Smerald G, Coaker R, Bloom E, et al. Working through Cancer. Surveying ex-
periences of cancer and work. Available from, https://www.macmillan.org.
uk/_images/working-through-cancer_tcm9-341781.pdf. [Accessed 6 July
2020].
[72] Wilson B. Five common misconceptions about Cancer at work. Available from,
https://www.thehrdirector.com/features/health-and-wellbeing/five-
common-misconceptions-cancer-work3292019/. [Accessed 6 July 2020].
